Anthony B. Evnin, PhD
Anthony B. Evnin, PhD
Partner, Venrock

Anthony B. Evnin, Ph.D. has been a Partner at Venrock, a venture capital firm, since 1975 and led Venrock’s entrance into and the first 25 years of its investments in biotechnology and the greater life sciences field.

Dr. Evnin currently serves on the Board of Directors of Juno Therapeutics, Cantel Medical, AVEO Pharmaceuticals, and Infinity Pharmaceuticals as well as two private companies. He was formerly a Director of over 40 companies, both public and private, in the life sciences area, including Centocor, Genetics Institute, IDEXX Laboratories, Dianon Systems, IDEC Pharmaceuticals, Athena Neurosciences, Sepracor, Triangle Pharmaceuticals, Caliper Life Sciences, Sugen, and Acceleron Pharma. He is a Member of the Boards of Overseers and Managers of Memorial Sloan Kettering Cancer Center, a Trustee of The Jackson Laboratory, a Director of the New York Genome Center, a Member of the Board of Directors of the Albert and Mary Lasker Foundation, a Trustee Emeritus of Princeton University, and a Trustee Emeritus of The Rockefeller University.

Dr. Evnin received an A.B. in chemistry from Princeton University and a Ph.D. in chemistry from the Massachusetts Institute of Technology.